BR112022016405A2 - Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento - Google Patents
Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamentoInfo
- Publication number
- BR112022016405A2 BR112022016405A2 BR112022016405A BR112022016405A BR112022016405A2 BR 112022016405 A2 BR112022016405 A2 BR 112022016405A2 BR 112022016405 A BR112022016405 A BR 112022016405A BR 112022016405 A BR112022016405 A BR 112022016405A BR 112022016405 A2 BR112022016405 A2 BR 112022016405A2
- Authority
- BR
- Brazil
- Prior art keywords
- voxelotor
- treatment
- pharmaceutical composition
- crystalline form
- crystalline forms
- Prior art date
Links
- FWCVZAQENIZVMY-UHFFFAOYSA-N 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(O)=C1C=O FWCVZAQENIZVMY-UHFFFAOYSA-N 0.000 title abstract 5
- 229940070141 voxelotor Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
FORMA CRISTALINA DE VOXELOTOR, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAMENTO, E, VOXELOTOR PARA USO NO TRATAMENTO. A presente invenção se refere às formas cristalinas de voxelotor, aos processos para a preparação deles, e às composições farmacêuticas contendo as formas cristalinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2002560.7A GB202002560D0 (en) | 2020-02-24 | 2020-02-24 | Crystalline forms of voxelotor, and processes for the preparation thereof |
PCT/GB2021/050380 WO2021170977A1 (en) | 2020-02-24 | 2021-02-17 | Crystalline forms of voxelotor, and processes for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016405A2 true BR112022016405A2 (pt) | 2023-01-10 |
Family
ID=70108361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016405A BR112022016405A2 (pt) | 2020-02-24 | 2021-02-17 | Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230126277A1 (pt) |
EP (1) | EP4110770A1 (pt) |
JP (1) | JP2023520619A (pt) |
KR (1) | KR20230015306A (pt) |
CN (1) | CN115768759A (pt) |
BR (1) | BR112022016405A2 (pt) |
CA (1) | CA3165764A1 (pt) |
GB (1) | GB202002560D0 (pt) |
WO (1) | WO2021170977A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023199345A1 (en) * | 2022-04-14 | 2023-10-19 | Msn Laboratories Private Limited, R&D Center | Novel solid state forms of voxelotor and their preparation methods thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3141542B1 (en) | 2011-12-28 | 2020-05-27 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
WO2015031285A1 (en) * | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
EP3868745A1 (en) * | 2014-02-07 | 2021-08-25 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
MA41841A (fr) * | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
TWI663160B (zh) * | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
-
2020
- 2020-02-24 GB GBGB2002560.7A patent/GB202002560D0/en not_active Ceased
-
2021
- 2021-02-17 BR BR112022016405A patent/BR112022016405A2/pt not_active Application Discontinuation
- 2021-02-17 CN CN202180015681.7A patent/CN115768759A/zh active Pending
- 2021-02-17 JP JP2022545390A patent/JP2023520619A/ja active Pending
- 2021-02-17 EP EP21708306.2A patent/EP4110770A1/en not_active Withdrawn
- 2021-02-17 KR KR1020227028176A patent/KR20230015306A/ko unknown
- 2021-02-17 CA CA3165764A patent/CA3165764A1/en active Pending
- 2021-02-17 WO PCT/GB2021/050380 patent/WO2021170977A1/en unknown
- 2021-02-17 US US17/904,889 patent/US20230126277A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB202002560D0 (en) | 2020-04-08 |
CN115768759A (zh) | 2023-03-07 |
KR20230015306A (ko) | 2023-01-31 |
EP4110770A1 (en) | 2023-01-04 |
CA3165764A1 (en) | 2021-09-02 |
JP2023520619A (ja) | 2023-05-18 |
WO2021170977A1 (en) | 2021-09-02 |
US20230126277A1 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
DOP2014000051A (es) | Imidazopiridazinas sustituidas con amino | |
EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
CL2013002185A1 (es) | Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih. | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
GT201300254A (es) | Triazolopiridinas | |
BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
CR20160433A (es) | Nuevos compuestos | |
BR112017013498B8 (pt) | Formulação agrícola, seu método de preparação, e composição agrícola aquosa | |
EA201600398A1 (ru) | Тиенопиримидины в качестве ингибиторов mknk1 и mknk2 | |
BR112014001083B8 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto | |
EA201791363A1 (ru) | Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2 | |
CR20160016A (es) | Pirazolpiridinas sustituidas | |
BR112022016405A2 (pt) | Forma cristalina de voxelotor, composição farmacêutica, método para tratamento, e, voxelotor para uso no tratamento | |
BR112015031820A2 (pt) | composto, composição farmacêutica, intermediário, processo para a preparação de um composto e métodos | |
CL2018003739A1 (es) | Formas cristalinas de un compuesto de tetraciclina sustituida con 9-aminometilo y un método para su preparación. | |
BR112022000229A2 (pt) | Composição para uso no tratamento da perda de cabelo | |
BR112021019437A2 (pt) | Composições de biofilme probiótico e métodos para preparar as mesmas | |
BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto | |
UY36983A (es) | Pirazolopiridinaminas sustituidas | |
UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
UY34630A (es) | Imidazopiridazinas sustituidas con amino |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |